oncodesign Sign Up Information

Dijon, France, September 10, 2020 – ONCODESIGN (ALONC – FR0011766229), a biopharmaceutical group specialized in precision medicine, today announces the launch of a reserved capital increase for the benefit of members of its Management Committee.

Philippe GENNE, Chairman and Chief Executive Officer of Oncodesign, says: “In recent months, the Management Committee has been working in unison to draw up our business plan through to 2025; we have set the Company ambitious targets, and we will give ourselves the means to achieve them. Through its participation in this capital increase, Oncodesign’s Management Committee wants to send out a strong and clear signal regarding its commitment to, involvement in and belief in the Oncodesign group’s development”.
 

To download the complete press release and PDF file, please click here

 

Dijon, France, December 17, 2020 – ONCODESIGN (ALONC – FR0011766229), a biopharmaceutical group specialized in precision medicine, is celebrating its 25th anniversary and announcing the launch of a new employee share ownership initiative. Carrying on from the capital increase subscribed for by the Executive Committee members in September, this transaction aims to foster engagement among the organization’s entire staff.

Philippe GENNE, Chairman and Chief Executive Officer of Oncodesign, says: “Giving all employees a stake in the organization’s share capital was one of our objectives this year, and we have adapted a three-stage approach—a capital increase reserved for Executive Committee members in September, the share ownership plan for Oncodesign’s top 20 key employees in December, and the establishment of a FCPE corporate mutual fund supporting our PEE corporate savings plan for all our employees in the first quarter of 2021. We have set ourselves ambitious development objectives for 2023, and we will equip ourselves to meet them. This employee share ownership plan is one of the measures we are taking to foster the engagement of all our teams and to demonstrate our trust in them. In the context of unprecedented global public health crisis, which is having a strong impact on the mobility of our Business Development teams and the delay in decision-making by our customers and our pharmaceutical partners, our strategic programs are still very much on track, as are our goals for the development of the Group. Giving Oncodesign’s employees a greater share in the Group’s performance is more than ever essential for the achievement of our objectives."

 

To download the complete press release and PDF file, please click here

 

Dijon, France, November 3, 2020 – ONCODESIGN (ALONC – FR0011766229), a biopharmaceutical group specialized in precision medicine, announced today the signature of a new multi-year service agreement (DDSA¹) with ViraTherapeutics, a subsidiary of Boehringer Ingelheim based in Innsbruck (Austria) and specialized in oncolytic viral immunotherapy².

Under this agreement, Oncodesign will play a key role for Austrian biotech company ViraTherapeutics, handling the preclinical assessment of its immunotherapy programs, which aim to develop next-generation vesicular stomatitis virus (VSV-GP) variants in immuno-oncology.

This two-year partnership deal falls within Oncodesign’s development strategy of supporting pharmaceutical and biotech companies during the early development stages of their therapeutic innovations under global strategic alliances.

“We are delighted that we will be working together under this agreement with ViraTherapeutics, a leading innovator in the development of oncolytic viral therapies and part of Boehringer Ingelheim. We are thrilled to be playing our part in their various ground-breaking oncology programs”, commented Fabrice Viviani, Managing Director and Head of the Oncodesign Services Business Unit.

“We are proud that ViraTherapeutics chose us as a key partner for conducting its oncolytic virus assessments. This partnership once again confirms the relevance and interest of the industry for our DDSA service offering. It is a tremendous encouragement to consolidate our efforts to put in place strategic agreements with innovative biotech companies and leading decision-makers in the pharmaceutical industry, in order to bring new therapeutic solutions to market as fast as possible to improve patient treatments and meet the strong therapeutic demand in oncology and infectious diseases”, added Philippe Genne, Chairman, Chief Executive Officer and Founder of Oncodesign.

 

To download the complete press release and PDF file, please click here
 

¹ Drug Discovery Strategic Alliance
² Oncolytic viral therapies use a virus designed to infect and replicate specifically in cancer cells, destroying those cells but leaving healthy cells untouched